Eupraxia Pharmaceuticals (NASDAQ:EPRX) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) from a hold rating to a sell rating in a research report released on Saturday.

EPRX has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. Cantor Fitzgerald boosted their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, January 15th. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $15.50.

Eupraxia Pharmaceuticals Trading Down 4.0%

NASDAQ:EPRX opened at $8.16 on Friday. Eupraxia Pharmaceuticals has a 1-year low of $2.68 and a 1-year high of $9.32. The business’s 50-day moving average price is $8.06 and its two-hundred day moving average price is $6.58. The firm has a market capitalization of $293.43 million, a price-to-earnings ratio of -9.38 and a beta of 1.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Ingalls & Snyder LLC bought a new position in shares of Eupraxia Pharmaceuticals during the second quarter valued at $214,000. XTX Topco Ltd bought a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter worth about $122,000. Raymond James Financial Inc. increased its position in Eupraxia Pharmaceuticals by 173.3% during the 3rd quarter. Raymond James Financial Inc. now owns 33,373 shares of the company’s stock valued at $197,000 after purchasing an additional 21,161 shares during the period. Jane Street Group LLC bought a new position in Eupraxia Pharmaceuticals during the 4th quarter worth approximately $223,000. Finally, Bank of America Corp DE lifted its position in shares of Eupraxia Pharmaceuticals by 262.9% in the 3rd quarter. Bank of America Corp DE now owns 45,577 shares of the company’s stock worth $269,000 after purchasing an additional 33,018 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.